TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00940732

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Feedback
Description: Written material delivered over 2 weeks via the Internet, including two short self-report measures (Goldberg Anxiety, Goldberg Depression), which will provide feedback to the participant about levels of depression and anxiety.
Study: NCT02729662

Intervention type: DRUG
Group type: OTHER
Intervention: Tolvaptan
Description: * Before administration of tolvaptan~  * TKV・Liver capacity: Once/year (an additional measurement within 3 months before start of administration)~ * 24-hour urine collection・Hematology/urinalysis: Once/year~ * Physical findings: Blood pressure and medical interview at ambulatory visit~* Hospitalization for education and examination at the start of tolvaptan administration~  * 24-hour urine collection・Hematology/urinalysis・Inulin clearance~ * Physical findings: Body weight, blood pressure~ * Adverse Events~* After administration of tolvaptan~  * TKV・Liver capacity・inulin clearance: Once/year~ * 24-hour urine collection: Once/6 months~ * Hematology/urinalysis: Once/month in principle~ * Physical findings: Blood pressure and medical interview at ambulatory visit~ * Adverse Events
Study: NCT04078633

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hand hygiene interventions
Description: Interventions are commonly used physical props for handwashing and commonly used hygiene promotion activities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hand hygiene interventions
Description: Interventions are commonly used physical props for handwashing and commonly used hygiene promotion activities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hand hygiene interventions
Description: Interventions are commonly used physical props for handwashing and commonly used hygiene promotion activities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hand hygiene interventions
Description: Interventions are commonly used physical props for handwashing and commonly used hygiene promotion activities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hand hygiene interventions
Description: Interventions are commonly used physical props for handwashing and commonly used hygiene promotion activities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hand hygiene interventions
Description: Interventions are commonly used physical props for handwashing and commonly used hygiene promotion activities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hand hygiene interventions
Description: Interventions are commonly used physical props for handwashing and commonly used hygiene promotion activities.
Study: NCT01474434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pradigastat (LCQ908)
Description: pradigastat tablets were supplied to the investigators at dose strengths of 10 mg and 20 mg as individual patient packs.
Study: NCT02796677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium bromide 400 μg/Formoterol Fumarate 12 μg (AB/FF 400/12 μg)
Description: Inhalation powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium bromide 400 μg (AB 400 μg)
Description: Inhalation powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol fumarate 12 μg (FF 12 μg)
Description: Inhalation powder

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo to AB/FF 400/12 μg, AB 400 μg and FF 12 μg
Description: Inhalation powder

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo to AB/FF 400/12 μg, AB 400 μg and FF 12 μg
Description: Inhalation powder

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo to AB/FF 400/12 μg, AB 400 μg and FF 12 μg
Description: Inhalation powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium 18 μg (TIO 18 μg)
Description: Powder in capsules for oral inhalation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo to TIO 18 μg
Description: Powder in capsules for oral inhalation
Study: NCT01686334

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC vaccine
Description: Autologous WT1 mRNA-electroporated DCs
Study: NCT04595552

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: language therapy
Description: auditory training and language therapy for 6 months up to 2 years in 2 session per week the duration of session 30 minuets
Study: NCT01532947

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: post placement
Description: placement of an endocanalar post
Study: NCT00831961

Intervention type: PROCEDURE
Intervention: Conjunctival and nasopharyngeal bacteria cultures
Description: Conjunctival and nasopharyngeal bacteria cultures

Intervention type: PROCEDURE
Intervention: Conjunctival and nasopharyngeal bacteria cultures
Description: Conjunctival and nasopharyngeal bacteria cultures

Intervention type: PROCEDURE
Intervention: Conjunctival and nasopharyngeal bacteria cultures
Description: Conjunctival and nasopharyngeal bacteria cultures

Intervention type: PROCEDURE
Intervention: Conjunctival and nasopharyngeal bacteria cultures
Description: Conjunctival and nasopharyngeal bacteria cultures
Study: NCT01525836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab; recombinant human thrombopoietin (rhTPO)
Description: patients in recombination treatment group take Rituximab( intravenously ,100 mg weekly for 4 consecutive weeks); in combination with Rh-TPO( subcutaneously , 300U/kg for 14 consecutive days,followed by flexible treating dosage so as to keep the platelet count above 50×10\^9/L until the 29th day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: patients in recombinant treatment group take Rituximab intravenously at 100 mg weekly for 4 consecutive weeks（Day 1,8,15,22)
Study: NCT01799707

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: vision restoration training
Description: visual stimuli repetitively presented to stimulate areas of residual vision. The training consists of luminance increment stimuli similar to perimetry and the task isa simple detection task (pressing a key whenever a target stimulus was detected).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Discrimination Training
Description: the stimulus is a line segment (bar) which is always presented within the central ±5° visual field in one of four possible random orientations: horizontal, vertical, oblique to the right or oblique to the left. If the patient has visual field defects in this central area, 80% of the stimuli are presented in the intact part of the training region. The task is to identify the orientation of the line segment and press, as fast as possible, one of 4 assigned buttons on the keyboard.
Study: NCT04051359

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low carbohydrate (130 g) diet
Description: Isocaloric moderately reduced carbohydrate diet (RCD, reduced carbohydrate diet) (\~130 grams of carbohydrates)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low carbohydrate (130 g) diet
Description: Isocaloric moderately reduced carbohydrate diet (RCD, reduced carbohydrate diet) (\~130 grams of carbohydrates)
Study: NCT02754973

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: an integrated experiential training program with coaching
Description: The intervention will be implemented to each participant by a designated coach who is a trained nursing student during 28 home visits throughout a 6-month period (24 weeks) and each visit will last for about 1 hour. The 1-hour program consists of a 30-minute English tutorial session, and a 30-minute physical activity session with the coach. The same coach will pay a visit to a participant at twice a week for the first 4 weeks and then once a week for the subsequent 20 weeks. 4 levels of physical activity will be taught to the participants gradually according to their ability.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: When discharged home, participants will receive an amount of time and attention (home visits by research assistants) that mimicked that received by the experimental group, but which is thought not to have any specific effect on the outcome measures. The placebo activities during the home visits may include playing cards or chess games, health advice on the prevention of influenza and healthy diet which will be conducted for 30 minutes.The participants will also receive a 30-minute English tutorial session with the research assistants in each home visit.
Study: NCT02805686

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: spectral domain optical coherence tomography
Study: NCT02805686

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: multifocal electroretinogram
Study: NCT02383563

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin extended release
Study: NCT01474434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo tablets
Study: NCT04702542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteral oxygen therapy
Description: Enteral oxygen therapy during the rehabilitation period of patients with CGDP.
Study: NCT02369146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UB-421
Description: The UB-421 (dB4C7 mAb) will be supplied at a concentration of 10 mg/mL (100 mg in 10 mL vial). Subjects will receive 8 doses of the UB-421 by intravenous infusion at 10 mg/kg weekly (Cohort 1, 8 weeks) or 25 mg/kg bi-weekly (Cohort 2, 16 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UB-421
Description: The UB-421 (dB4C7 mAb) will be supplied at a concentration of 10 mg/mL (100 mg in 10 mL vial). Subjects will receive 8 doses of the UB-421 by intravenous infusion at 10 mg/kg weekly (Cohort 1, 8 weeks) or 25 mg/kg bi-weekly (Cohort 2, 16 weeks).
Study: NCT01424449

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [11C]PHNO
Description: examine the effects of \[11C\]PHNO mass carry-over and displaceable binding

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: A 4th scan will follow a 15mg dose of aripiprazole (a D2/D3 compound which allows the highest clinically acceptable blockade of central D2/D3 receptors)
Study: NCT03002831

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cytokine-induced Killer Cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur-Gimeracil-Oteracil Potassium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tegafur-Gimeracil-Oteracil Potassium
Study: NCT02483000

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo autologous PBSCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clearing Agent
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Indium In 111-DOTA-Biotin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo autologous PBSCT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Yttrium Y 90-DOTA-Biotin
Description: Given IV
Study: NCT01560468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITX 5061
Description: 300 mg given orally beginning at the time of liver transplantation and for 1 week post-transplant followed by 150 mg orally for an additional 21 days.
Study: NCT03410368

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK cells
Description: Autologous peripheral blood mononuclear cells (PBMCs) are collected by apheresis on D0, then induced into NK cells and infused into the patients 14 days later (D14) as the initial transfusion. There are 3 consecutive transfusion days (D14-D16). The second course of PBMCs collection started D14 before infusion. A total of 6 courses will be completed unless progression or unacceptable adverse events.
Study: NCT01581359

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triptorelin acetate
Description: * Triptorelin acetate Dosing regimen: 1 subcutaneous injection of 3,75 mg/28 days, total of 3 doses~* Placebo Dosing regimen: subcutaneous injection of the same volume of physiological serum/28 days, total of 3 doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Triptorelin acetate
Description: * Triptorelin acetate Dosing regimen: 1 subcutaneous injection of 3,75 mg/28 days, total of 3 doses~* Placebo Dosing regimen: subcutaneous injection of the same volume of physiological serum/28 days, total of 3 doses
Study: NCT02270918

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kcentra
Description: IV infusion
Study: NCT01120366

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab plus methotrexate
Description: Tocilizumab 8mg/kg 4weeks (i.v.) plus methotrexate up to 52weeks.The dosage of MTX will be fixed at least 24 weeks from the start of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Description: tocilizumab 8mg/kg/4weeks (i.v.) up to 52weeks.
Study: NCT03470688

Intervention type: BIOLOGICAL
Intervention: Originator
Description: Originator anti-TNF agents

Intervention type: BIOLOGICAL
Intervention: Biosimilar
Description: Biosimilar anti-TNF agents
Study: NCT02167308

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Laser acupuncture
Description: a GaAlAs semiconductor diode Laser Phototherapy Device with a wavelength of 808nm. Maximum power output is 150 milliwatt in continuous wave mode.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser acupuncture
Description: a GaAlAs semiconductor diode Laser Phototherapy Device with a wavelength of 808nm. Maximum power output is 150 milliwatt in continuous wave mode.
Study: NCT04403412

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Left atrial appendage closure group
Description: Left atrial appendage closure Left atrial appendage closure is performed using a single endocardial plug devices guided by fluoroscopic guidance and transesophageal echocardiography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation group
Description: Radiofrequency ablation Each patient with persistent AF receives circumferential pulmonary vein isolation under the 3D electro-anatomical mapping system , and no additional ablation is performed in the extrapulmonary sites unless the patient is diagnosed with atrial flutter before the operation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LAAC combined with radiofrequency ablation group
Description: LAAC combined with radiofrequency ablation group Each patient received the same group of patients with simple radiofrequency ablation radiofrequency ablation treatment at the same time, the transcatheter occlusion of left atrial appendage opening
Study: NCT03082248

Intervention type: OTHER
Group type: OTHER
Intervention: Physical Therapy
Description: Patients allocated to the conservative treatment group will receive physical therapy according to the treatment-based classification approach and also educational leaflets and folders.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Spinal Surgery
Description: Patients allocated to the surgical procedure group will undergo spinal surgery procedures and techniques specific for the low back region.
Study: NCT01753622

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise group
Description: Supervised physical conditioning program of three 55-60 minute sessions per week during whole pregnancy (from week 9 to 38). Each session consists of 25-30 minutes of cardiovascular exercise, 10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training.~Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60 of maximal heart rate. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate.
Study: NCT02270918

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Study: NCT04412577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3473
Description: TQB3473 tablets administered orally once. Then TQB3473 tablets administered orally, once daily in 28-day cycle after 3 days of first administration.
Study: NCT01412177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTO-104
Description: Single intratympanic injection of 12 mg OTO-104

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single intratympanic injection of placebo
Study: NCT02270918

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Apixaban

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00901433

Intervention type: DEVICE
Intervention: Personal WheezoMeter
Description: pulmonary sounds analyzer
Study: NCT02418676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gel with HPβCD-I complex
Description: Initially, the pressure ulcer was cleaned with saline. With the aid of a paper ruler, the ulcer was measured and photographed, as the ruler included the date and the initials of the patient. After measuring, a quantity of 5 grams of gel with hydroxypropyl-beta-cyclodextrin complexed with insulin (HPβCD-I) was placed on the pressure ulcer and covered with sterile gauze and a transparent film.~The curative was changed once a day during the treatment period, unless there was leakage of fluid, contamination, or signs of infection. Every three days the pressure ulcers of all patients were measured and photographed again, resulting in a total of six measurements per patient. The photos of pressure ulcers were evaluated for measurement of pressure ulcers and any kind of irritation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gel with insulin
Description: Initially, the pressure ulcer was cleaned with saline. With the aid of a paper ruler, the ulcer was measured and photographed, as the ruler included the date and the initials of the patient. After measuring, a quantity of 5 grams of gel with insulin was placed on the pressure ulcer and covered with sterile gauze and a transparent film.~The curative was changed once a day during the treatment period, unless there was leakage of fluid, contamination, or signs of infection. Every three days the pressure ulcers of all patients were measured and photographed again, resulting in a total of six measurements per patient. The photos of pressure ulcers were evaluated for measurement of pressure ulcers and any kind of irritation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control gel
Description: Initially, the pressure ulcer was cleaned with saline. With the aid of a paper ruler, the ulcer was measured and photographed, as the ruler included the date and the initials of the patient. After measuring, a quantity of 5 grams of control gel was placed on the pressure ulcer and covered with sterile gauze and a transparent film.~The curative was changed once a day during the treatment period, unless there was leakage of fluid, contamination, or signs of infection. Every three days the pressure ulcers of all patients were measured and photographed again, resulting in a total of six measurements per patient. The photos of pressure ulcers were evaluated for measurement of pressure ulcers and any kind of irritation.
Study: NCT02373943

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: β-carotene biofortified maize
Description: Determination of all-trans retinol AUC values after the ingestion of 200 g porridge made with 50 g of flour of β-carotene fortified maize
Study: NCT01860664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrocortisone ophthalmic ointment 0.5%
Description: * Patients will be instructed to apply Hydrocortisone Ophthalmic Ointment 0.5% or placebo in the lower cul de sac or lid margin BID~* Patients will be instructed to not use the study medications at least 2 hours prior to their appointment.~* Study medication dosing details:~  * 0.05 grams hydrocortisone per gram of combination product~ * each application equal to 1/20th of a gram~ * total amount of active ingredient applied to each eye per application = 0.0025 grams hydrocortisone~ * total amount hydrocortisone applied per eye per day = 0.005 grams hydrocortisone~ * Total amount of active ingredient applied per eye throughout duration of the two week study = 0.07 grams hydrocortisone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Mineral oil and white petrolatum
Study: NCT01447589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nelfinavir
Description: Nelfinavir tablets BD 7 days per week from D-7 of starting radiotherapy until completion of radiotherapy on D47. 3 dose levels: 750 mg bd; 1000 mg bd; and 1250 mg bd.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radical Radiotherapy
Description: Total dose of 66 Gy delivered in 33 fractions (2.0 Gy/fraction) to the primary tumour plus a margin.
Study: NCT02003235

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Daily watching videos using Reviview™, a dichoptic video display device, for 60 min
Study: NCT02682381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teduglutide 0.05mg/kg
Description: 0.05 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teduglutide 0.025 mg/kg
Description: 0.025 mg/kg

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Observational cohort for the 24-week treatment period and 4 week follow-up.